Evaluation of high-dose rifampin in patients with new, smear-positive tuberculosis (HIRIF): study protocol for a randomized controlled trial

BACKGROUND: Evidence has existed for decades that higher doses of rifampin may be more effective, but potentially more toxic, than standard doses used in tuberculosis treatment. Whether increased doses of rifampin could safely shorten treatment remains an open question. METHODS/DESIGN: The HIRIF stu...

Descripción completa

Detalles Bibliográficos
Autores principales: Milstein, Meredith, Lecca, Leonid, Peloquin, Charles, Mitchison, Denis, Seung, Kwonjune, Pagano, Marcello, Coleman, David, Osso, Elna, Coit, Julia, Vargas Vasquez, Dante Elmo, Sanchez Garavito, Epifanio, Calderon, Roger, Contreras, Carmen, Davies, Geraint, Mitnick, Carole D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5002098/
https://www.ncbi.nlm.nih.gov/pubmed/27567500
http://dx.doi.org/10.1186/s12879-016-1790-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5002098/
https://www.ncbi.nlm.nih.gov/pubmed/27567500
http://dx.doi.org/10.1186/s12879-016-1790-x

Ejemplares similares